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Abstract Cardiomyocytes proliferate profusely during
early development and for a brief period after birth in
mammals. Within a month after birth, this proliferative
capability is dramatically reduced in mammals unlike
lower vertebrates where it persists into adult life. The
zebrafish, for example, retains the ability to regenerate the
apex of the heart following resection by a mechanism
predominantly driven by cardiomyocyte proliferation.
Differences in proliferative capacity of cardiomyocytes in
adulthood between mammals and lower vertebrates are
closely liked to ontogenetic or phylogenetic factors. Elu-
cidation of these factors has the potential to provide
enormous benefits if they lead to the development of
therapeutic strategies that facilitate cardiomyocyte prolif-
eration. In this review, we highlight the differences
between Mammalian and Zebrafish cardiomyocytes, which
could explain at least in part the different proliferative
capacities in these two species. We discuss the advantages
of the zebrafish as a model of cardiomyocyte proliferation,
particularly at the embryonic stage. We also identify a
number of key molecular pathways with potential to reveal
key steps in switching cardiomyocytes from a quiescent to
a proliferative phenotype.
Keywords Zebrafish  Mammals  Heart  Proliferation 
Regeneration
Introduction
Ischaemic heart disease is the commonest cause of heart
failure in developed countries either as a consequence of
acute myocardial infarction or chronic ischaemic damage
[1]. In addition the impact of an ageing population with
degenerative cardiac disease associated with hypertension
or valvular heart disease also contributes to cardiomyocyte
dysfunction, loss and ultimately heart failure [2–4]. In the
face of injury and progressive loss of cardiomyocytes, the
human heart typically responds with hypertrophy combined
with hyperplasia of non-cardiomyocyte cell populations in
the heart including fibroblasts [5].
Embryonic and fetal hearts of most vertebrates, includ-
ing mammals, typically show some degree of regenerative
capacity, although studies in neonatal mice suggest it can
last for up to 7 days after birth [6]. The limited capacity of
the adult mammalian heart to restore lost cardiomyocytes
following injury contrasts starkly with the highly effective
regenerative process in adult hearts from lower vertebrates
including amphibians and fish. Recently, the underlying
mechanisms of heart regeneration in the adult zebrafish
have become clearer with evidence that mature car-
diomyocytes dedifferentiate, re-enter the cell cycle and
then proliferate to support repair and replacement of
injured myocardium [7, 8]. The zebrafish embryo has also
contributed significantly to elucidate mechanisms of car-
diac growth and development [9]. Despite being a two-
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chambered organ, the zebrafish heart exhibits many simi-
larities to the mammalian heart and cellular and molecular
studies clearly illustrate the common evolutionary origin of
these structures [10]. Since the regenerative process
appears to reactivate developmental pathways [11],
understanding zebrafish cardiac development also helps us
to understand the powerful cardiac regenerative ability in
the adult zebrafish heart. A key question is whether a better
understanding of the zebrafish cardiac regenerative process
provides important insights into the mammalian response
to injury and repair, and it remains an exciting challenge to
determine if the regenerative capacity of the mammalian
heart could be harnessed as a therapeutic strategy with
significant clinical value.
There is no doubt, however, that the zebrafish represents
an interesting model in which to study cardiomyocyte
proliferation and cardiomyocyte hyperplasia following
injury. One major advantage of utilizing zebrafish embryos
for studies of cardiogenesis is that the embryo is able to
survive for several days without a functioning cardiovas-
cular system. This permits the study of cardiac phenotypes
that would otherwise be lethal in mammalian model sys-
tems [12]. This review examines the differences and
similarities in the response of mammals and zebrafish to
cardiac injury. We also highlight several unique properties
of the zebrafish embryo as a model of cardiomyocyte
proliferation.
Cardiomyocyte proliferation: from early embryos
to adulthood
Embryonic development
The heart is the first organ to visibly form and function
during embryogenesis [13]. In Vertebrates, cardiogenesis is
a morphologically complex process that involves sequen-
tial heart primordia migration, folding, looping, septation
and maturation to form the chambered heart. The following
description of heart development applies mainly to the
mammalian heart although many aspects also apply to the
zebrafish, and chicken heart. During embryogenesis, pro-
liferation of new cardiomyocytes is the main source for the
heart growth. Cardiomyocytes proliferate along the heart
tube walls and within the atrioventricular septum. In par-
ticular, the outer surface of the heart, also called the
compact region [14], achieves the highest proliferative rate.
The epicardium, the thin layer of cells enveloping the
heart, provides a source of mitogenic signaling that stim-
ulate proliferation of cardiomyocytes within the compact
zone [15]. A key epicardial-derived regulator of cardiac
growth includes retinoic acid and its related receptors [16].
Newly formed cardiomyocytes thicken the ventricular wall
and organize fingerlike projections along the inner ventri-
cle surface giving rise to trabeculae, structures that increase
force of contraction and improve oxygen and nutrient
exchange for the heart itself. The endocardium, the spe-
cialized single-cell inner layer of the heart, also provides
fundamental growth signals for embryonic cardiomy-
ocytes, including peptides of the neuregulin family and
their related tyrosine kinase receptors [17]. These growth
factors also play an important role in promoting the normal
‘‘ballooning’’ of the outer curvature of the ventricle [18].
The intense cardiomyocyte proliferative activity observed
during embryonic heart growth is accompanied by
increasing intra-cavity shear forces that contribute to the
shaping of the early heart [19].
Fetal to adulthood transition
While cardiomyocytes divide extensively and rapidly dur-
ing fetal life, in mammals they lose their proliferative
capacity shortly after birth. The proliferative activity of
murine cardiomyocytes starts to decrease around E10–12
[20]. One key molecular player at this stage is Jumonji
(jarid2) that acts to inhibit cardiomyocyte proliferation
through repression of cyclin D1 expression. Jumonji
appears to repress cyclin D1 transcription by recruiting
histone H3–K9 methyltransferases, G9a and GLP, to the
cyclin D1 promoter [21]. Indeed, jarid2 mutant mice
demonstrate increased proliferation and overexpression of
cyclin D1 in cardiomyocytes at E10 [22] [20].
In humans, cardiomyocyte proliferative capacity is lost
by a few months after birth when cardiomyocytes withdraw
from the cell cycle and remain in G0 stage, apparently
indefinitely [23–26], a process called terminal differentia-
tion. Downregulation of several fetal genes and
upregulation of genes responsible for the adult phenotype
play important roles in this process. Cyclin-dependent
kinases (CDKs) play a core functional role in the cell cycle
machinery. Sequential activation of different CDKs,
forming complexes with their specific cyclins, allows
progression of the cell cycle. In mammals, CDK4/6–cyclin
D is activated in phase G1, CDK2–cyclin E in phase G1/S,
CDK2/1–cyclin A in phase S/G2 and CDK1–cyclin B in
phase M. Diminished CDK activity leads to attenuation or
cessation of the cell cycle. The expression and activity of
many cyclins and CDKs change synchronously during
embryonic and postnatal developmental stages [27], sug-
gesting a highly orchestrated series of cellular mechanisms
controlling their role in proliferation. CDKs are regulated
by CDK inhibitors (CKIs) including the INK4 family (p15,
p16, p18 and p19) and Cip/Kip family (p21, p27 and p57)
[27]. CKIs participate in termination of postnatal mam-
malian cardiomyocyte cell cycle as demonstrated in p21
and p27 knockout mice, where cardiomyocytes exit the cell
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cycle at G1-phase [28]. Meis1 is a transcriptional factor
that is known to activate p21 and regulate cardiac cell cycle
exit [29]. In fact, cardiomyocyte proliferative activity is
prolonged after birth in Meis1 KO mice.
The cardiomyocyte cell cycle appears closely coupled to
the accumulation of cell mass during development which
acts to maintain consistent cell size [30]. In most species,
this transition from hyperplastic-to-hypertrophic activity is
characterized by changes in degree of ploidy and number
of nuclei as cardiomyocytes undergo additional DNA
replication followed by cytokinesis and/or karyokinesis
[31, 32] (Fig. 1). The higher number of mononucleated and
diploid cardiomyocytes in species capable of cardiac
regeneration, such as newt [33], zebrafish [34] and rodent
fetal and neonates [6, 35–37], suggest a higher proliferation
capacity in such cells.
Indeed, Bersell et al. [38] demonstrated that only
mononucleated cardiomyocytes that respond to the acti-
vation of the neuregulin 1/ErbB4 pathway after cardiac
injury in mice initiate cardiomyocyte proliferation. Adult
human cardiomyocytes are mostly mononucleated and
tetraploid (4n), and adult mice cardiomyocytes are mainly
binucleated and diploid (2n) [39] (Fig. 1). Indeed, several
reports have shown a gradual decrease in the incorporation
of radiolabeled thymidine soon after birth, coinciding with
the formation of binucleated cardiomyocytes in mice
[35, 40]. This process is associated with an increase in
myofibril density and the formation of mature intercalated
discs [41].
Fetal to adulthood temporal transition represents the
divide between cardiac regenerating and non-regenerating
species and it is, therefore, a key stage in which to study
differences in cell cycle exit between species.
Adulthood
During the twentieth century, it was believed that the heart
is a post-mitotic organ and cardiac growth in the adult was
attributed exclusively to cardiomyocyte hypertrophy
[42–45]. However, since the 1990s, evidence of car-
diomyocyte proliferation in adult human hearts has been
gradually accepted [46–48]. Quaini and co-workers
demonstrated the presence of proliferating cell nuclear
antigen, a marker of the G1–S cell cycle phases, in adult
human hearts with ischemic and dilated cardiomyopathy.
Evidence of metaphasic chromosomes together with
cytokinesis was demonstrated in normal myocardium and
in ischemic and dilated cardiomyopathy and in myocardial
infarction [46, 47]. Considerable disagreement remains on
the frequency of these cellular events in adult normal and
diseased adult myocardium [49]; however, there appears to
be a clear cardiac cellular response to disease and injury
[39, 50]. The measured rate of cell division is influenced by
the methods used to detect DNA synthesis and count car-
diomyocytes [35, 50]. Radiocarbon birth dating has shown
Fig. 1 Cardiomyocyte cellular structure across species. Zebrafish and
newt are mostly mononucleated and diploid [59, 154]; an organization
that seems to favour a higher proliferative response to injury. Rodents
show either mono- or bi-nucleated diploid cardiomyocytes [38].
Following stress or injury, mostly, these cardiomyocytes respond with
hypertrophy; however, only those mononucleated cells appear to
initiate proliferation. Human cardiomyocytes are mostly mononucle-
ated and tetraploids. Limited data in young humans up to 20 years
old, suggest that cardiomyocytes have some proliferative capacity
[51, 52]. However, in later life, hypertrophy is the predominant
response to injury in human
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that cardiomyocyte turnover is approximately 1% over
20–40-year-old hearts [51]. A more recent study using new
confocal imaging and optical dissector method suggested
that cardiomyocyte division contributes to heart growth in
young humans up to 20 years of age, with a cardiomyocyte
turnover of approximately 1.9% [52]. Some reports have
shown that adult rat cardiomyocytes can proliferate in
culture after treatment with FGF1 concomitant with
p38MAP kinase inhibition [25]. Indeed, normal adult car-
diomyocytes rarely appear to re-enter the cell cycle and
proliferate [41], and terminally differentiated mammalian
cardiomyocytes show a predominantly hypertrophic
response to mitogenic stimuli [53, 54]. One significant
difference between embryonic and adult heart is the
expression of cell cycle promoters, such as CDKs, cyclins,
and proto-oncogenes, markedly expressed in embryonic
hearts, corresponding to high cardiomyocyte cell cycle
activity, while their expression is lower in the adult heart.
In general, negative cell cycle regulatory genes, such as
CDK inhibitors, are upregulated in adult hearts, where
cardiomyocyte cell cycle activity is extremely low [41].
There is now a well-recognized link between mam-
malian cardiomyocyte hypertrophy and proliferation which
involves a complex series of interconnected signaling
pathways, including JAK, PLC, JNK, ERK, calcineurin,
STAT, RAS, and MEF2 [5]. In addition to an increase in
cellular RNA and protein, hypertrophy results in tran-
scriptional reprogramming that closely resembles the fetal
gene program that is known to drive hyperplasia in the
developing fetus [55, 56]. It is hypothesized that car-
diomyocyte hypertrophy, without hyperplasia, in mammals
might be the result of a fundamental block in karyokinesis
and cytokinesis by which the adult cardiomyocyte is unable
to disassemble sarcomeres, uncouple from neighbouring
cells and divide [57].
Mammals and zebrafish
Compared to mammals, cardiomyocytes from lower ver-
tebrates, including teleost fish and salamander, show high
proliferative capacity in adulthood [58]. The molecular
mechanisms underlying this trait are not well understood.
Better understanding could potentially provide important
therapeutic targets for a range of cardiac disorders where
cardiomyocyte loss plays a major role. A relevant differ-
ence between mammalians and zebrafish is that, in the
latter, cardiomyocytes do not undergo cytokinetic mitosis.
In fact, the majority of cardiomyocytes in adult zebrafish
continue to have a single nucleus and a diploid genome
(2n), similar to that observed in fetal mammalian hearts
(vide supra) and associated with significant proliferative
ability [59]. There is a common set of genes that drive
growth and development of the embryonic heart in
mammals [60] and fish [61]. A similar gene program is
activated in the adult mammalian heart following injury or
haemodynamic stress [5, 62, 63]. Many of these genes also
appear to be activated in response to resection of the
ventricle apex in the zebrafish [8, 64]. While this process
has been studied in a variety of mammalian animal models,
less is known about the related processes in the adult
human heart.
Becker and colleagues [65] created and analysed a
transgenic zebrafish embryo carrying a mutation in the
troponin (tnnt2) gene associated with hypertrophic car-
diomyopathy (HCM) in humans. An important finding in
this model was that although the mutant gene resulted in
abnormal sarcomeric organization, similar to that observed
in humans and mouse models with HCM, the zebrafish
exhibited a hyperplastic rather than a hypertrophic pheno-
type. Thus, the response of the zebrafish to stress or injury
appears to be, primarily, a hyperplastic response, in con-
trast to mammals where the response is almost exclusively
one of hypertrophy.
The heart’s response to injury: hypertrophy
versus hyperplasia
In mammals
A variety of mechanisms are present in all organisms for
dealing with tissue damage resulting from injury or disease.
Mammals can regenerate liver, pancreas and skin, and can
partially repair injury of peripheral nerves or skeletal
muscle, but retain poor regenerative ability of other organs
[66].
While the adult mammalian heart is considered a ter-
minally differentiated organ, the fetal heart retains a
remarkable proliferative capacity, capable of regenerating
cardiomyocytes following injury [67, 68]. Porrello and
colleagues [6] have shown that neonatal mouse car-
diomyocytes can regenerate following surgical resection of
the apex of the left ventricle. However, by day 7, the
regenerative capacity is lost and replaced by a more clas-
sical fibrotic response resulting in scar tissue and impaired
cardiac function. This finding has re-energized the search
for mechanisms that underpin cell cycle arrest in the
mammalian heart, with the intention of pursuing key
molecular targets that might induce mature mammalian
cardiomyocytes to re-enter the cell cycle.
Following transmural myocardial infarction (MI) in
adult rats and human, the typical response to injury is
inflammation and ventricular remodeling with a fibrotic
scar forming at the site of MI [69, 70] (see Table 1).
Reparative fibrosis appearing within and around the MI
region is essential to safeguard the structural integrity of
1370 G. Matrone et al.
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infarcted tissue, although interstitial fibrosis in non-in-
farcted myocardium alters tissue stiffness and can lead to
ventricular dysfunction [71]. Following such injury,
mammalian myocardium typically responds with car-
diomyocyte hypertrophy combined with hyperplasia of
non-cardiomyocyte cell populations in the heart including
fibroblasts [5]. Cardiac hypertrophy, characterized by an
increased cardiomyocyte size, enhanced protein synthesis
and re-organization of the sarcomere [72], is acknowledged
as an adaptive response intended to preserve cardiac
function in the face of increasing haemodynamic stress.
This physiological response normalizes wall tension and is
necessary in the short term to allow the animal to adapt to
the initial myocardial loss or haemodynamic load [5].
However, more prolonged stress converts this to a patho-
logical process where a prolonged stimulus to cardiac
hypertrophy leads to abnormal cellular responses within
the myocardium typified by interstitial fibrosis, a switch to
less-efficient myosin types and abnormal calcium handling
[73]. These features result in so-called adverse remodeling
of the ventricle and, in addition to contractile dysfunction,
can lead to congestive cardiac failure and its fatal sequelae
of progressive pump failure or sudden arrhythmic death.
Apoptosis is also a feature of cardiac hypertrophy partic-
ularly when associated with congestive heart failure [74].
However, evidence has emerged that the adult mammalian
heart does contain a small population of progenitor cells
capable of differentiating into cardiomyocytes [75]. These
cells might play a role in the replacement of lost car-
diomyocytes [76–78], although they do not appear to be
activated as part of a replacement process [59].
Nevertheless, the presence of active DNA synthesis
[35], even if low, and the presence of putative progenitor
cells within the hearts of adult mammals, gives rise to the
possibility that proliferation of adult cardiomyocytes could
be stimulated therapeutically as part of a process that could
support repair and recovery. Why existing cardiac pro-
genitor cell populations are unable to repair cardiac muscle
in response to injury and, most importantly, how to trigger
this untapped resource, are not yet clear.
Currently, many laboratories and institutions around the
world are focused on the engraftment of various types of
progenitor cells into infarcted hearts to achieve myocardial
tissue renewal [79–83]. To date, most of these studies
suggest that, while there may be small improvements in
cardiac function, there is little evidence, in both human and
mouse models, that such progenitors truly engraft and
mature into active cardiomyocytes [84, 85]. There is evi-
dence, however, that they may increase angiogenesis,
leading many to believe that progenitor cells release a
variety of growth factors that contribute to the response to
injury by stimulating growth and repair of non-cardiomy-
ocyte-derived cells [86–88].
The zebrafish
While mammals lose the ability to regenerate the heart
within a few weeks after birth, lower vertebrates, such as
amphibians and fish, retain this ability to regenerate the
heart, and, indeed, most of their organs, following signifi-
cant injury or loss of tissue well into adulthood (see table).
In the zebrafish, resection of up to 20% of the ventricle
apex results in complete regeneration and repair of the
ventricle within 60 days [89]. Zebrafish heart regeneration
proceeds through injury-induced proliferation of car-
diomyocytes which retain their capacity to divide and
proliferate postnatally [33, 89–91]. BrdU labelling studies
have shown BrdU-positive cardiomyocytes along the
leading edge of the regenerating heart. Lepilina and co-
workers [92] suggested that regenerating myocardium
arises and matures from undifferentiated cardiomyocyte
progenitor cells of epicardial origin. In contrast, two more
recent genetic fate-mapping studies [7, 11] unambiguously
demonstrated that pre-existing committed cardiomyocytes
are, in fact, the main source of the cells contributing to
cardiac regeneration in the zebrafish.
Thus, although cellular mechanisms involved in cardiac
regeneration have recently been unraveled, the molecular
pathways that might be involved in initiating and main-
taining the cardiomyocyte response to injury remain
uncertain. Further studies are required to clarify these
mechanisms that induce a hyperplastic, and not a hyper-
trophic, response in this setting. Genetic similarity between
humans and zebrafish [93, 94] support the notion that
cardiac regenerative pathways can be dissected in the fish
model.
Table 1 Comparative scheme outlining the cardiac response to injury in mammals versus zebrafish
Human Mice Zebrafish
Response to injury Fibrosis followed by cardiomyocyte hypertrophy Cardiomyocyte proliferation
Cardiac injury end-point Heart failure/contractile dysfunction Normal functionality re-established
Regenerative potential Unknown Up to 7 days after birth in mice Lifelong
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Zebrafish embryo as a model of cardiomyocyte
proliferation
The zebrafish heart is emerging as an increasingly flexible
model to study many developmental, genetic and acquired
cardiac disorders [95]. Zebrafish heart development is well
characterized [9, 96–98] adding to numerous early publi-
cations on this topic [99, 100]. Despite having only two
chambers, the fish heart retains many of the structural and
developmental components of the mammalian heart [101],
including a three-layer ventricular wall (epicardium,
myocardium and endocardium) from three days post fer-
tilization [102, 103]. The early mammalian heart is derived
from first and second heart fields [102, 103], although there
is evidence that a population of lateral mesoderm-derived
haemangioblasts represent an evolutionary antecedent of
the second heart field in zebrafish [104].
The zebrafish embryonic heart is particularly suited to
studying aspects of cardiomyocyte proliferation for a
number of important reasons. First, the embryonic heart in
the early stages is composed of only a few hundred car-
diomyocytes [105, 106], and this allows accurate and
reproducible approaches to count total cardiomyocyte
number in either chamber or both. In addition, transgenic
technology using fluorescent proteins [107, 108] can be
targeted to developing cardiomyocytes, which allows the
ready visualization of in vivo development and function of
these cells [109].
The small size of the zebrafish embryo permits exchange
of gases by passive diffusion, allowing their survival and
relatively normal development for several days even in the
absence of a functioning heart and circulation [110]. This
permits the phenotypic analysis of embryos with severe or
lethal cardiovascular mutations and defects [111, 112]
which would otherwise be extremely difficult to assess in
higher vertebrates where they would be highly likely to die
in utero [13].
There are no well-described models of myocardial
infarction or cardiac hypertrophy in lower vertebrates akin
to those developed and exploited over many years in small
mammals [113]. To circumvent this problem, researchers
have developed more radical approaches of resecting a
piece of the ventricle. This was first reported in salaman-
ders [114] and then in the zebrafish, where approximately
20% of the ventricle apex can be resected, and regrowth
will occur within 60 days [89]. This model has now been
reproduced in many laboratories around the world and has
become a standard approach to studying the molecular and
cellular mechanisms associated with cardiomyocyte pro-
liferation leading to what has come to be known as cardiac
regeneration. However, this resection model is only feasi-
ble in a low-pressure heart such as that found in lower
vertebrate species and in the early postnatal time period in
mice. In a high-pressure haemodynamic system, typical of
adult mammalian hearts, acute bleeding from the resection
margin results in rapid death. Not only does this indicate
that the injury response to heart resection is different in
zebrafish due to the underlying physiology, but it also
poses the question of whether repair of a resected piece of
heart by cardiomyocyte proliferation is likely to convey an
evolutionary advantage for mammals since it would most
likely result in exsanguination from the heart itself.
Arguably, therefore, the best option for a mammalian
heart, working at higher physiological pressures, and faced
with a large zone of injury is to generate an area of scar
tissue as quickly as possible in order to heal the infarcted
territory and avoid the risk of myocardial rupture and
bleeding that would ensue [115]. In addition, since this
ventricle apex resection is not as physiologically or clini-
cally relevant as a model [116], others have used
cryoinjury in which liquid nitrogen is used to injure a
localised region of ventricle in a regional manner similar to
myocardial infarction [117, 118]. Following this cryoin-
jury, the adult zebrafish heart demonstrates features
consistent with regeneration including cardiomyocyte
proliferation, but in this case, there is also a more readily
observed area of scar which requires up to 3 months for
complete repair.
Mechanisms controlling organ and tissue regeneration
are conserved between larvae and adults at the cellular and
molecular levels, suggesting that the regenerative
machinery directing cell proliferation in response to injury
may exist from early developmental stages [119]. Indeed,
amputation of either the adult or embryo zebrafish fin, a
widely used model of tissue regeneration, induces prolif-
eration of progenitor cells from the amputation margin
[120]. In the same model, at molecular level, transcription
factors and components of various signaling pathways
normally upregulated during adult fin regeneration [121]
are also increased during larval regeneration [119–121].
We have recently developed and validated a model of
heart injury and recovery in the zebrafish embryo using
highly targeted laser injury [122] (supplementary movie).
The use of embryos significantly shortens the injury
response and subsequent repair time period. We have
demonstrated a striking ability of the zebrafish embryonic
heart to regenerate and recover cardiac function by 24 h
post-laser injury. Using this approach, the zebrafish embryo
can be used in a high-throughput model system to study
human disease. For example, figure S1 clearly shows a
protocol to study heart response to injury that can be
completed in an experiment over a period of only 4–5 days.
Embryos can be injected at 1–2 cell stage with one or more
compounds, such as labelled mRNA, for overexpressing
genes, or CRISPR/Cas 9 for gene knockout or morpholino
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oligonucleotides for gene knockdown (figure S1A).
Otherwise, embryos can be exposed to small molecules and
pharmacological compounds of interest by simply adding
these to the medium at the desired developmental stage
(figure S1B). Embryos can then be injured, for example
using a targeted laser at 72 hpf as described, followed by
collection of data of cardiac function, including ejection
fraction and tail blood flow (figure S1C). Using transgenic
lines expressing fluorochrome driven by cardiac markers,
such as tg(myl:gfp)y1 in figure S1D, hundreds of embryonic
hearts can be isolated in a few minutes, for immunohisto-
chemistry, gene and protein analysis (Figure S1E). The
laser injury technique also lends itself to a high-throughput
approach; it is possible to create a standardised level of
heart injury to the ventricle in approximately 50 embryos
per hour. We have also applied the laser-induced injury to
different cardiac regions and structures in the zebrafish
larva, including bulbus arteriosus and atrioventricular valve
and have demonstrated the potential of the zebrafish to be
used for various models of cardiac disease [123]. Although
the overlying tissue, the pericardium in this case, is also
partially injured, this is proportionately less compared to
existing surgical approaches (apical resection, cryoinjury)
in adults requiring damaging tissue layers covering the
heart, making our model more myocardial-specific.
Using the laser-induced injury model, we have explored
a number of molecular pathways that could enhance
recovery from myocardial injury. In particular, we
explored the relationships between cyclin-dependent kinase
(CDK)9, La-related protein (LARP)7 and the positive
transcription elongation factor (P-TEF)b complex of which
they are molecular partners. CDK9 has been implicated in
mammal cardiac hypertrophy [124]. In our experiments,
we first downregulated CDK9 and or LARP7 by pharma-
cological or morpholino knockdown and found that they
had mainly opposite effects, to CDK9 strongly reducing its
action and LARP7 slightly increasing cardiomyocyte pro-
liferation [125]. In separate experiments, we found that
prior CDK9 downregulation impaired the cardiac recovery
from laser injury, whereas LARP7 knockdown did not.
Interestingly, co-injection of LARP7 and CDK9-targeted
morpholinos rescued the CDK9 phenotype, both in terms
of cardiomyocyte proliferation and cardiac function. We
concluded that LARP7 acts to maintain CDK9 in an
inactive state in the P-TEFb complex and that suppressing
LARP7 activity results in a derepression of CDK9 that
ultimately leads to a more active P-TEFb complex.
Studying the repair process following injury during car-
diogenesis and development clearly raises some questions
of relevance of these experiments to the mammalian heart.
However, compared to the adult, the zebrafish larva not
only offers the advantage to study hundreds of animals
over a short time period, but it also allows the possibility to
study severe developmental cardiac defects which would
otherwise be extremely challenging to study in mammalian
models. High-throughput drug screening programs, for
example, have been successfully used in zebrafish to
explore novel therapeutic candidates before moving for-
ward to more expensive mammalian model systems
[126–128].
Molecular pathways linked to cardiomyocyte
proliferation as targets for drug development
Several molecular pathways are under investigation for
their potential ability to inhibit or activate cardiomyocyte
growth and or proliferation and could be harnessed to
develop heart disease therapies (Fig. 2). In some cases, the
role of these pathways in cardiomyocyte proliferation has
been unraveled in zebrafish. For example, a balance
between CDK9 and its repressors, including LA-Related
Protein 7, can switch on or off cardiomyocyte proliferation
in zebrafish [125]. However, CDK9 knockdown affects
somatic growth and development of a number of key
embryonic structures including the brain, heart, eye and
blood vessels [129]. For therapeutic strategies, this raised
the question to develop tissue- or cell-specific anti-CDK9
drugs. The activity of the P-TEFb complex, a key driver for
transcription formed by CDK9 and cyclin T, is increased in
cardiac hypertrophy in mammals [124]. In addition, the
CDK9 activity is derepressed by the dissociation of 7SK
small nuclear RNA [130, 131] and HEXIM1 [132, 133],
two CDK9 inhibitors. HEXIM1 knockout mice die during
fetal development and exhibit all the genetic and physical
hallmarks of cardiac hypertrophy [134]. CDK9 has also
been shown to regulate cell cycle and is involved in
Fig. 2 Schematic representation of possible molecular pathways that
could be targeted therapeutically to promote cardiomyocyte prolifer-
ation in mammals (see text)
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cardiomyocytes differentiation from mice embryonic stem
cells [135]. Mahmoud and colleagues [29] showed that in
neonatal and adult cardiomyocytes, Meis1 deficiency
increases cardiomyocyte numbers, whereas Meis1 overex-
pression activates CDK inhibitors INK4b-ARFINK4a and
Cdkn1a genes, which leads to cell cycle arrest because of
inhibition of CDKs. miRNAs are also potential targets for
cardiomyocyte proliferation therapies (Fig. 2) [136]. As
miRNAs generally repress gene expression by promoting
mRNA degradation and/or by inhibiting translation, the
final effects on cardiomyocte proliferation are mediated by
inhibiting or activating the cell cycle [137, 138]. For
example, miR-590 and miR-17/92 clusters promote car-
diomyocyte proliferation by inhibiting the proliferation
repressors Homer protein homolog 1 (Homer1) and
Homeodomain-only protein x (Hopx), whereas miR-15
family represses cardiomyocyte proliferation by inhibiting
the proliferative activator Checkpoint kinase 1 (Check1).
Furthermore, the muscle-specific microRNA-1 (miR-1),
which normally keeps CDK9 derepressed at the transcrip-
tional level [139], was downregulated at a very early stage,
following cardiac hypertrophy induced in a mouse model
of aortic constriction-induced hypertrophy.
Also, the Hippo/Yap pathway plays an essential role in
the regulation of heart development and postnatal car-
diomyocyte proliferation [140], highlighting the potential
for enhancing cardiac regeneration (Fig. 2) [141]. Indeed,
modulation of this pathway in the neonatal heart has
been shown to prolong the regenerative window. However,
Hippo/Yap also appears to influence cardiomyocyte
autophagy and apoptosis [142]. Among the mitogens, IGF2
has been shown to activate cardiomyocyte proliferation and
is required for zebrafish heart regeneration [143], whereas
TGFb/activin signaling plays important roles in car-
diomyocyte proliferation and scar formation [144].
Modulation of inflammation may provide a key thera-
peutic strategy to drive heart regeneration. Indeed, the
types of macrophage present in the regenerating neonatal
mouse heart may provide essential stimuli for angiogenesis
and regeneration [145].
Hypoxia, redox signaling and metabolic phenotypes are
also key regulators of cardiomyocyte proliferation and
cardiac renewal [146]. Puente et al. [147] have recently
shown that cell cycle arrest in postnatally terminally dif-
ferentiated cardiomyocytes is triggered by mitochondrial
reactive oxygen species-mediated oxidative DNA damage.
This suggests that ROS may play key roles in cell cycle
regulation and differentiation during cardiac development.
In turn, this suggests that cells responsible for cellular
turnover in the heart, such as immature and/or mature
myocytes or progenitor population may need an environ-
ment with a lower oxygen concentration to proliferate
efficiently. The heart may be unique in the nature of this
oxygen-sensitive response. On the one hand, it has high O2
consumption [148], and on the other hand, its cardiac
progenitor cells appear to benefit from hypoxic precondi-
tioning which improves survival and homing of engrafted
cells into an infarcted territory [149]. Indeed, the epi-
cardium and subepicardium regions contain multipotent
progenitor cells [150] which could represent a novel
hypoxic niche of the heart. These cells express Hif1a and
respond to hypoxia by increasing cell proliferation and,
thus, provide a source of new cardiac cells following injury
including fibroblasts, perivascular smooth muscle cells
[151] and cardiomyocytes after thymosin b4 activation
[144, 145, 152]. A better understanding of these and other
molecular mechanisms would allow us to develop exciting
new strategies to improve cardiomyocyte proliferation and
cardiac regeneration.
Future perspectives
The question remains as to how drugs or therapeutic
stategies could be used to support cardiac repair in disease
conditions where the heart was failing or at risk of failing
following injury, stress or cell loss. Clearly, a key time for
treatment would be around the time of an acute myocardial
infarction where many previous studies of bone-marrow-
derived stem cells have been extensively tested over the
last 10 years [153] with overall, relatively disappointing
results.
The possibility of directly harnessing cellular mecha-
nisms to achieve therapeutic benefit in patients with both
heart disease remains elusive. To date, the possibility of
providing therapies targeted at enhancing cardiomyocyte
proliferation that could either be administered acutely, at
the time of acute injury such as infarction, or in the long
term to patients with chronic left ventricular systolic dys-
function remains an important but elusive target. The key
issue would be whether such drugs could be administered
orally or intravenously and whether their benefits out-
weighed the risk of harm. At this stage, we are a long way
from knowing the answers to these questions since no
viable candidate drug has yet been developed despite a
number of interesting pathways currently undergoing fur-
ther studies. Any such drug with the capacity to reactivate a
highly differentiated cardiomyocyte into a more active
proliferative state is likely to carry a significant risk of
inducing unregulated cell growth either in the target tissue
or in other exposed tissues. The risk of neoplasia is,
therefore, clear unless the drug can be highly targeted to a
specific cardiac pathway or delivered in a highly localised
manner directly to the heart.
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